Currently Viewing:
ACC.20/WCC Virtual Experience
VICTORIA Results to Headline ACC's First-Ever Virtual Meeting
March 14, 2020
CVD Risk Faces Undue Influence From Social Determinants of Health
March 18, 2020
Statins May Protect Heart From Breast Cancer Therapy Damage
March 19, 2020
Hypertension-Related Deaths Rise in US, Especially in Rural South, Data Show
March 21, 2020
Currently Reading
Dr Richard Kovacs Discusses the Virtual Shift of ACC.20/WCC 2020 and Upcoming Scientific Highlights
March 25, 2020
VICTORIA: With Vericiguat, Less CV Death, Heart Failure Hospitalization Among High-Risk Patients
March 28, 2020
Dr Javed Butler on Key Takeaways of Vericiguat Found in VICTORIA Trial Participants With HFrEF
March 28, 2020
VOYAGER-PAD: Less Risk of Events With Rivaroxaban After Treatment for Blocked Arteries
March 28, 2020
Dr Richard Kovacs on How ACC Is Leading the Charge for Credible Clinical Data Amid COVID-19
March 28, 2020
Apixaban, Dalteprin Shown to Have Same Bleeding Risk in Patients With Cancer
March 29, 2020
Q&A: A Discussion on Hypertension, ISCHEMIA, and Aortic Stenosis
March 29, 2020
Dr Javed Butler Notes Subgroup Efficacy Differences of Vericiguat in VICTORIA Trial Findings
March 29, 2020
Is Anatomy Destiny? Digging Deeper Into the ISCHEMIA Findings
March 29, 2020
Q&A: An Indirect Comparison of Andexanet Alfa, Prothrombin Complex Concentrate in Patients With NOAC-Related Bleeding
March 30, 2020
A Q&A on Risk, Management of Bleeding-Related Hospitalizations
March 30, 2020
REDUCE-IT: Serum EPA Levels Hold Key to Vascepa's Dramatic CV Benefits
March 30, 2020
Evinacumab Brings Cholesterol to Near-Normal Levels for Patients With Rare, Inherited Condition
March 30, 2020
A Q&A on Smoking Cessation With E-Cigarettes, REDUCE-IT Trial Findings
March 30, 2020

Dr Richard Kovacs Discusses the Virtual Shift of ACC.20/WCC 2020 and Upcoming Scientific Highlights

We have our featured research that we're going to bring—our keynotes, our Young Investigator Awards presentations, and we're going to have some special emphasis on global health, especially relevant in terms of the COVID-19 pandemic, said Richard Kovacs, MD, FACC, clinical cardiologist and president of the American College of Cardiology (ACC).


We have our featured research that we're going to bring–our keynotes, our Young Investigator Awards presentations, and we're going to have some special emphasis on global health, especially relevant and in terms of the COVID-19 pandemic, said Richard Kovacs, MD, FACC, clinical cardiologist and president of the American College of Cardiology (ACC).

Transcript

Can you describe the process of guiding ACC to the decision of delivering a virtual program?

The American College of Cardiology came to the decision fairly early on that our annual meeting was not going to be able to be held in the current environment. So, we went through the usual Kübler-Ross stages of anger, denial, and grief, and then we thought about what could we do? 

So we quickly broke down into what were the parts of the meeting, and we decided that there was a very intellectual part of the meeting with science and education, but there was also an emotional and a social part of the meeting with our ceremonies, our opening event, our convocation, and all the social interactions that go on. Then there's a business part of the meeting with our industry partners and our exhibits. We looked at how we could accomplish each of those–we decided with social distancing that it was going to be very difficult to have those social interactions, but that we could maintain part of that community aspect to the meeting. 

We also felt that it was very, very necessary for us to push the science that had been developing over the course of the year forward. Finally, our fellows in training and the people who are presenting abstracts and being on the national stage for the very first time in their career, we thought that was also critically important. So, we integrated all those into our virtual meeting.

What do you think will be the scientific highlights of the program?

Certainly we're going to bring forth all of our late breaking clinical trials as part of the program. We have our featured research that we're going to bring–our keynotes, our Young Investigator Awards presentations, and we're going to have some special emphasis on global health, especially relevant and in terms of the COVID-19 pandemic. We also have some emphasis on cardio obstetrics. Our late breakers span the areas of heart failure, of revascularization, of prevention, of ischemic heart disease treatments, and so we're going to see a very broad and deep program.

 
Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up